Catalog No.
EQJ05001
Expression system
Mammalian Cells
Species
Canis lupus familiaris (Dog) (Canis familiaris)
Protein length
Ser24-Gln159
Predicted molecular weight
18.27 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
C7G0W1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
IL-31, Interleukin-31, IL31,
Reconstructed Epidermis Produced with Atopic Dog Keratinocytes Only Exhibit Skin Barrier Defects after the Addition of Proinflammatory and Allergic Cytokines., PMID:39811760
Trichohyalin gene expression is negatively correlated with the severity of dermatitis in a canine atopic dermatitis model., PMID:39234173
Long-term use of lokivetmab in dogs with atopic dermatitis., PMID:39143659
Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine., PMID:38932349
Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis., PMID:38926932
Characterisation of the pruritus responses and pruritic behaviours in an interleukin 31-induced canine model of pruritus., PMID:38149639
Interleukin-31 in serum and cerebrospinal fluid of dogs with syringomyelia., PMID:37993920
Non-controlled, open-label trial to assess clinical and immunological parameters in atopic dogs feeding monoprotein grain free diet versus a standard grain diet., PMID:37530035
Characterization of the serum and skin inflammatory profile in canine pemphigus foliaceus using multiplex assay and quantitative real-time polymerase chain reaction (qRT-PCR)., PMID:37473673
Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab., PMID:37389418
Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL-31 inhibition with lokivetmab., PMID:37006124
Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs., PMID:36842258
The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis., PMID:35644533
Development and characterization of a novel mouse anti-canine oncostatin M receptor beta monoclonal antibody., PMID:35576682
Mesenchymal Stem Cells and Extracellular Vesicles Derived from Canine Adipose Tissue Ameliorates Inflammation, Skin Barrier Function and Pruritus by Reducing JAK/STAT Signaling in Atopic Dermatitis., PMID:35563259
Comparison of circulating CD4+, CD8+ lymphocytes and cytokine profiles between dogs with atopic dermatitis and healthy dogs., PMID:35134678
Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma., PMID:34866072
IL-31 and IL-31 receptor expression in acute experimental canine atopic dermatitis skin lesions., PMID:34796564
Cytokine expression in feline allergic dermatitis and feline asthma., PMID:34519120
A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis., PMID:34180084
Expression of barrier proteins in the skin lesions and inflammatory cytokines in peripheral blood mononuclear cells of atopic dogs., PMID:34075152
Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus., PMID:33830571
Evaluation of the cutaneous expression of IL-17, IL-22, IL-31, and their receptors in canine atopic dermatitis., PMID:33588097
Serum concentrations of IL-31 in dogs with nonpruritic mast cell tumours or lymphoma., PMID:32985732
Combined IMIG and Immune Ig Attenuate Allergic Responses in Beagle Dogs., PMID:32377529
Interleukin 31 in insect bite hypersensitivity-Alleviating clinical symptoms by active vaccination against itch., PMID:31816097
Alterations in circulating concentrations of IL-17, IL-31 and total IgE in dogs with atopic dermatitis., PMID:31218782
Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis., PMID:30479052
The effect of an ex vivo boosted immune cell therapy on canine atopic dermatitis: an open, uncontrolled pilot study., PMID:30226281
Evaluation of immunological parameters in pit bull terrier-type dogs with juvenile onset generalized demodicosis and age-matched healthy pit bull terrier-type dogs., PMID:30141276
A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA., PMID:30141223
Vaccination against IL-31 for the treatment of atopic dermatitis in dogs., PMID:29627081
Transcriptional analysis of the IL-33 receptor suppression of tumourigenicity 2 and its effects on canine Type 2 T helper cells: a preliminary study., PMID:29178475
Investigation of the correlation of serum IL-31 with severity of dermatitis in an experimental model of canine atopic dermatitis using beagle dogs., PMID:28983982
Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis., PMID:28670717
Cockroach allergen exposure and plasma cytokines among children in a tropical environment., PMID:28668242
A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis., PMID:27647569
A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis., PMID:27647513
Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody., PMID:27501029
Early Activation of Th2/Th22 Inflammatory and Pruritogenic Pathways in Acute Canine Atopic Dermatitis Skin Lesions., PMID:27342734
IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics., PMID:26666963
Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy., PMID:24495176
Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells., PMID:24321252
Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis., PMID:23331679
Molecular cloning of canine interleukin-31 and its expression in various tissues., PMID:19409622
For research use only. Not for human or drug use.
